Short-course treatment for low-risk active lung TB
Part of Infections, Lungs & breathing clinical trials.
This trial tests a shorter treatment course (instead of the standard 6 months) for people with low-risk active TB in the lungs. It aims to see if the shorter regimen works just as well and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 20 years old.
- You have been newly diagnosed with active TB in your lungs, confirmed by a lab test (culture or PCR) or by a doctor's judgment.
- You have not taken TB medications for more than 14 days before joining.
- Your liver and kidney function are within safe limits (based on blood tests).
- You do not have TB that is resistant to common antibiotics (rifampin, isoniazid, ethambutol).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two existing medicines (pyrazinamide and hydroxychloroquine) to see if it works as well as the current standard treatment for TB. If it works, it could mean fewer pills or a shorter treatment for patients with drug-sensitive TB.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
This study tests a shorter-course treatment for tuberculosis (TB) in people 65 and older. It compares a new ultra-short regimen to the usual longer one, using the drugs bedaquiline, linezolid, and pyrazinamide, to see if a shorter treatment is just as effective and safer for older adults.
Hear when a new Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.